Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Arizona
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage I-III estrogen receptor positive breast cancer (positive for estrogen receptor (ER)) with positivity defined as immunohistochemical staining in ≥ 10% of cells) on adjuvant hormonal therapy with aromatase inhibitors (anastrozole, letrozole or exemestane)
Adults over 18 years of age with a life expectancy of at least 3 months
Attained menopause as defined by World Health Organization Criteria (defined as permanent cessation of menstruation resulting from the loss of ovarian follicular activity. This is recognized to occur after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause.)
Persistent genitourinary symptoms causing discomfort for more than 2 weeks prior to the visit with the physician.
Tried at least 1 prior pharmacological/ non-pharmacological treatment for their genitourinary symptoms
Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to any study specific procedures
Be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory tests and other study procedures
You may not be if
Patients with metastatic breast cancer
Have a concurrent active non-breast malignancy except for non-melanoma skin cancer
Patients with vaginal stenosis
Patients unable to apply Estring
Clareo Health | Estradiol Levels in Patients Treated With Estring
